Xingkerong Pharmaceuticals (06833) released its six-month performance ending on June 30, 2024, with a profit of 1.527 billion yuan (RMB) , a year-on-year increase of 40.1%; net income of 23.87 million yuan, a year-on-year increase of 21.8%; and basic earnings per share of 0.0117 yuan.

Compared to the same period in 2023, the gross margin during the reporting period decreased from 14.0% to 11.3%. The decrease in profit margin was mainly due to the decrease in gross margin of human serum albumin, which was caused by the depreciation of the RMB against the US dollar and the increase in procurement costs.